Biotechnology (12) | Waiver Agreements (12)

Browse by Company

Recent Contracts

Form of Waiver Agreement, dated as of February 3, 2021, by and between Ocuphire Pharma, Inc. and the Holder(s) (REXAHN PHARMACEUTICALS, INC., Filed With SEC on February 4, 2021)
Waiver, dated January 20, 2021, by and among Cerevel Therapeutics Holdings, Inc. and the investors party thereto (ARYA Sciences Acquisition Corp II, Filed With SEC on January 21, 2021)
Amendment Number 1 and Waiver Agreement dated December 20, 2018 by and between Helio Vision, Inc. and the Massachusetts Eye and Ear Infirmary (Aldeyra Therapeutics, Inc., Filed With SEC on March 12, 2020)
Form of Series A Conversion Waiver (NANOVIRICIDES, INC., Filed With SEC on January 8, 2020)
Form of Series A Conversion Waiver (NANOVIRICIDES, INC., Filed With SEC on January 7, 2020)
Form of Series A Conversion Waiver (NANOVIRICIDES, INC., Filed With SEC on December 23, 2019)
Form of Series A Conversion Waiver (NANOVIRICIDES, INC., Filed With SEC on December 17, 2019)
Form of Series A Conversion Waiver (NANOVIRICIDES, INC., Filed With SEC on November 29, 2019)
Form of Consent and Waiver with Series B Convertible Preferred Stockholders (RITTER PHARMACEUTICALS INC, Filed With SEC on November 14, 2019)
Waiver Letter to Voting Agreement (Chardan Healthcare Acquisition Corp., Filed With SEC on November 4, 2019)